Benzinga

Benzinga

Benzinga

domingo, agosto 30

Bioventus Inc

BVSNASDAQ
Trade with Public
Trade with Public
$13.84
0.050.36%
al cierre: Aug 28, 5:00 PM EST
$13.84
N/A
After hour: Aug 28, 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Bioventus Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bioventus (BVS).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$15Upside to Avg. PT+7.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Canaccord GenuityCaitlin CroninPT RaiseBuy$15→$19
Aug 17, 2026Cantor FitzgeraldSarah JamesMaintainedOverweight$15
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19

Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Bioventus, Raises Price Target to $14

Barrington Research analyst Michael Petusky maintains Bioventus (NASDAQ:BVS) with a Outperform and raises the price target from $13 to $14.
Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $16

Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $16.
Benzinga Newsdesk

This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

PRO
Barrington Research Initiates Coverage On Bioventus with Outperform Rating, Announces Price Target of $13

Barrington Research analyst Michael Petusky initiates coverage on Bioventus (NASDAQ:BVS) with a Outperform rating and announces Price Target of $13.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved